RT Journal Article
SR Electronic
T1 Tenofovir-DF versus Hydroxychloroquine in the Treatment of Hospitalized Patients with COVID-19: An Observational Study (TEDHICOV)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.24.21252635
DO 10.1101/2021.03.24.21252635
A1 Cornejo-Giraldo, Mario
A1 Rosado, Nelson
A1 Salinas, Jesús
A1 Aspilcueta, Nelson
A1 Bernales, Eduardo
A1 Lipa, Jimmy
A1 Coacalla, Johanna
A1 Flores, Yoisi
A1 Leon, Pamela
A1 Chamby, Claudia
YR 2021
UL http://medrxiv.org/content/early/2021/04/26/2021.03.24.21252635.abstract
AB Background Although several therapeutic agents have been suggested for the treatment of the disease caused by the Coronavirus of the year 2019 (COVID-19), no antiviral has yet demonstrated consistent efficacy.Methods The results of an observational study comparing Tenofovir-DF (TDF) with Hydroxychloroquine (HCQ) in the treatment of hospitalized patients with COVID-19 with evidence of pulmonary compromise and the vast majority with supplemental oxygen requirement are presented. Patients received HCQ consecutively at the dose of 400 mg. 12 hourly for 01 day and then 200 mg. every 8 to 12 hours PO for 5 to10 days; or TDF 300 mg. per day PO for 7 to 10 days. The primary outcomes of the study were the differences between the two groups regarding: hospital stay, the need for intensive care or mechanical ventilation (ICU / MV) and mortality.Results 104 patients were included: 36 in the HCQ group and 68 in the TDF group. The unadjusted primary outcomes were: LOS (length of stay) 16.6 ± 12.1 for HCQ versus 12.2 ± 7.0 days for TDF (p = o.o102); need for admission to ICU / mechanical ventilation (MV): 61.1% for HCQ versus 11.8% for TDF (p = o.ooo); and mortality: 50.0% for HCQ and 8.8% for TDF (p = o.ooo). The patients in the HCQ group had significant differences at admission compared to those in the TDF group regarding: male sex, cardiovascular risk factor, greater respiratory involvement and higher glucose and creatinine levels, lower albumin levels and higher. Inflammatory markers. When the outcomes were adjusted for these baseline differences, in the multiple regression model for LOS, it was found that TDF decreased the hospital stay by 6.10 days (C.I.: −11.97 to −2.40, p = o.o42); In the logistic regression model for the need for ICU / MV, it was found that the use of TDF had an O.R. of 0.15 (C.I.: 0.03-0.76, p = o.o22); and for the Cox proportional hazards model for mortality, the H.R. was 0.16 for TDF (C.I.: 0.03-0.96, p = o.o41). In the estimation model of the treatment effects by regression adjustment, it was found that TDF decreased the stay by −6.38 days (C.I.: −12.34 to −0.42, p = o.o36); the need for ICU / MV at −41.74% (C.I.: −63.72 to −19.7, p = o.ooo); and mortality by −35.22% (C.I.: −56.47 to −13.96, p = o.oo1).Conclusion TDF may be an effective antiviral in the treatment of COVID-19. Some of its advantages include: its wide availability, cost and oral presentation. Randomized clinical trials are imperatively required to confirm this possibility.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04812496Funding StatementNo external funding source was available for this study. It was a self-funded study by the authorsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Review/Human Subjects Review: Board Status: Approved. Approval Number: NIT:2803/ 2021/07. Board Name: Comite Institucional de Etica en Investigacion de la Red Asistencial Arequipa (RAR) / EsSalud. Board Affiliation: Instituto Nacional de Salud / Peru, RCEI-83 / IETSI.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data on which this study is based are available at https://drive.google.com/file/d/1JADVw7uUkbbZLE7VphnvvkvzlGV1WdRr/view?usp=sharing